<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00729443</url>
  </required_header>
  <id_info>
    <org_study_id>D0490C00012</org_study_id>
    <secondary_id>EudractCT# 2008-002466-62</secondary_id>
    <nct_id>NCT00729443</nct_id>
  </id_info>
  <brief_title>Investigating Safety, Tolerability and Pharmakinetics When Giving Single and Fractionated Doses of AZD3241 to Healthy Volunteers</brief_title>
  <acronym>SAD</acronym>
  <official_title>A Single-Centre, Placebo-Controlled, Randomized, Double-Blind Study to Evaluate the Safety, Tolerability and Pharmacokinetics of AZD3241 Following Administration of Single Ascending (Part A) and Fractionated Ascending (Part B) Oral Doses to Young Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is carried out in order to investigate safety, tolerability and pharmacokinetics
      after administrating single and fractionated doses of AZD3241 to healthy volunteers
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2008</start_date>
  <completion_date type="Actual">November 2008</completion_date>
  <primary_completion_date type="Actual">November 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>General tolerability and safety variables</measure>
    <time_frame>2 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>pk</measure>
    <time_frame>approximately 48 hour</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">64</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD3241</intervention_name>
    <description>single oral dose</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provision of informed consent

          -  Body Mass Index (BMI) 19 to 30 kg/m2 inclusive

          -  Clinically normal physical findings, including BP, pulse rate, ECG and laboratory
             findings, as judged by the investigator

        Exclusion Criteria:

          -  Clinically significant illness within the 2 weeks prior to the administration of the
             investigational product

          -  Heart rate (resting, recumbent) &lt;50 bmp or &gt;85 bmp

          -  History of severe allergy/hypersensitivity or ongoing allergy/hypersensitivity as
             judged by the investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ingemar Bylesjö</last_name>
    <role>Principal Investigator</role>
    <affiliation>Astrazeneca Clinical Pharmacology Unit, Stockholm, Sweden</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>November 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 4, 2008</study_first_submitted>
  <study_first_submitted_qc>August 6, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 7, 2008</study_first_posted>
  <last_update_submitted>November 10, 2008</last_update_submitted>
  <last_update_submitted_qc>November 10, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 13, 2008</last_update_posted>
  <responsible_party>
    <name_title>Jarkko Kalliomäki, MD, Medical Science Director, Neuroscience alpha</name_title>
    <organization>AstraZeneca R&amp;D Södertälje, Sweden</organization>
  </responsible_party>
  <keyword>Single dose</keyword>
  <keyword>Phase 1</keyword>
  <keyword>Safety of AZD3241</keyword>
  <keyword>tolerability of AZD3241</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

